scholarly journals Why participation in an international clinical trial platform matters during a pandemic? Launching REMAP-CAP in Japan

2021 ◽  
Vol 9 (1) ◽  
Author(s):  
Kazuhiro Kamata ◽  
Kazuaki Jindai ◽  
Nao Ichihara ◽  
Hiroki Saito ◽  
Hideaki Kato ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Clinical Trials ◽  
Healthcare Workers ◽  
Emerging Infectious Diseases ◽  
Community Acquired Pneumonia ◽  
Global Network ◽  
Front Line ◽  
Multiple Stakeholders ◽  
Governmental Agencies ◽  
International Clinical Trial

AbstractREMAP-CAP, a randomized, embedded, multifactorial adaptive platform trial for community-acquired pneumonia, is an international clinical trial that is rapidly expanding its scope and scale in response to the COVID-19 pandemic. Japan is now joining REMAP-CAP with endorsement from Japanese academic societies. Commitment to REMAP-CAP can significantly contribute to population health through timely identification of optimal COVID-19 therapeutics. Additionally, it will promote the establishment of a national and global network of clinical trials to tackle future pandemics of emerging and re-emerging infectious diseases, in collaboration with multiple stakeholders, including front-line healthcare workers, governmental agencies, regulatory authorities, and academic societies.

Iranian clinical trials: An analysis of registered trials in International Clinical Trial Registry Platform (ICTRP)

2017 ◽  
Vol 10 (2) ◽  
pp. 91-96 ◽  
Author(s):  
Mansoureh Feizabadi ◽  
Fatima Fahimnia ◽  
Alireza Mosavi Jarrahi ◽  
Nader Naghshineh ◽  
Shahram Tofighi
Keyword(s):  
Clinical Trial ◽  
Clinical Trials ◽  
Trial Registry ◽  
Clinical Trial Registry ◽  
International Clinical Trial

scholarly journals International Clinical Trial Day and clinical trials in Ethiopia and Africa

Trials ◽  
2014 ◽  
Vol 15 (1) ◽  
Author(s):  
Abebaw Fekadu ◽  
Solomon Teferra ◽  
Asrat Hailu ◽  
Tsige Gebre-Mariam ◽  
Adamu Addissie ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Clinical Trials ◽  
International Clinical Trial

Planning the Size of Clinical Trials with Allowance for Patient Noncompliance

1990 ◽  
Vol 29 (03) ◽  
pp. 243-246 ◽  
Author(s):  
M. A. A. Moussa
Keyword(s):  
Clinical Trial ◽  
Clinical Trials ◽  
Sample Size ◽  
Event Rate ◽  
Survival Functions ◽  
Time Intervals ◽  
Patient Noncompliance ◽  
Event Rates ◽  
Larger Sample

AbstractVarious approaches are considered for adjustment of clinical trial size for patient noncompliance. Such approaches either model the effect of noncompliance through comparison of two survival distributions or two simple proportions. Models that allow for variation of noncompliance and event rates between time intervals are also considered. The approach that models the noncompliance adjustment on the basis of survival functions is conservative and hence requires larger sample size. The model to be selected for noncompliance adjustment depends upon available estimates of noncompliance and event rate patterns.

Front-line Healthcare Workers in COVID-19: The Way from Elbow-Bump Greeting to Closing Body Bags

2020 ◽  
Author(s):  
Stefan Bittmann
Keyword(s):  
Health Service ◽  
Healthcare Workers ◽  
Well Being ◽  
The United States ◽  
Angiotensin Ii Receptor ◽  
Front Line ◽  
Resource Center ◽  
Research Activities ◽  
The World ◽  
The Usa

COVID-19 is a serious coronavirus disease that is spreading all over the world. As of the date of this publication, 2.834.134 people have been infected with COVID-19 and 197.924 deaths have been recorded in 185 countries (John Hopkins Corona Resource Center, 25th April 2020) [1]. This overwhelming mortality rate requires intensive research activities around the world. To date, the number of deaths per day in the United States is still killing, indicating an uncontrollable state of infection spread. SARS-CoV-2 binds to the angiotensin II receptor in various tissues of the human body, particularly in the oral cavity and tongue. SARS-CoV-2 requires the cheerful TMPRSS2 to activate this inertia. SARS-CoV-2 uses the ACE2 receptor as a gateway to the lungs. The SARS-CoV-2 virus binds with the spike protein to the ACE2 receptor. COVID-19 is more common among African Americans in the USA (Science 10th April 2020). The comfort and the emotional loading capacity of the employees in the health service are key components for the maintenance of the essential health services during the outbreak of the COVID-19 virus (Coronavirus) [2,3]. Hence, it will be important to anticipate the charges linked with this work and to release support for employees in the health service. The supervision and assessment of the psychic health and the well-being of the employees in the health service will be important, just as the efforts to guarantee a successful reunion with colleagues if they are infected.

Repurposed Antiviral Drugs for the Treatment of COVID-19: Syntheses, Mechanism of Infection and Clinical Trials

2020 ◽  
Vol 21 ◽  
Author(s):  
Subha Sankar Paul ◽  
Goutam Biswas
Keyword(s):  
Public Health ◽  
Clinical Trial ◽  
Clinical Trials ◽  
Small Molecule ◽  
Mode Of Action ◽  
Antiviral Drugs ◽  
Public Health Emergency ◽  
Advanced Stage ◽  
Clinical Trial Results

: COVID-19 is a public health emergency of international concern. Although, considerable knowledge has been acquired with time about the viral mechanism of infection and mode of replication, yet no specific drugs or vaccines have been discovered against SARS-CoV-2, till date. There are few small molecule antiviral drugs like Remdesivir and Favipiravir which have shown promising results in different advanced stage of clinical trials. Chloroquinine, Hydroxychloroquine, and Lopinavir-Ritonavir combination, although initially was hypothesized to be effective against SARS-CoV-2, are now discontinued from the solidarity clinical trials. This review provides a brief description of their chemical syntheses along with their mode of action and clinical trial results available in Google and different peer reviewed journals till 24th October 2020.

Sign in / Sign up

Export Citation Format

Share Document